• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >The pilot European Alzheimer's disease neuroimaging initiative of the European Alzheimer's disease consortium
【2h】

The pilot European Alzheimer's disease neuroimaging initiative of the European Alzheimer's disease consortium

机译：欧洲阿尔茨海默氏病联盟的欧洲阿尔茨海默氏病神经成像试点计划

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: In North America, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has established a platform to track the brain changes of Alzheimer's disease. A pilot study has been carried out in Europe to test the feasibility of the adoption of the ADNI platform (pilot E-ADNI). Methods: Seven academic sites of the European Alzheimer's Disease Consortium (EADC) enrolled 19 patients with mild cognitive impairment (MCI), 22 with AD, and 18 older healthy persons by using the ADNI clinical and neuropsychological battery. ADNI compliant magnetic resonance imaging (MRI) scans, cerebrospinal fluid, and blood samples were shipped to central repositories. Medial temporal atrophy (MTA) and white matter hyperintensities (WMH) were assessed by a single rater by using visual rating scales. Results: Recruitment rate was 3.5 subjects per month per site. The cognitive, behavioral, and neuropsychological features of the European subjects were very similar to their U.S. counterparts. Three-dimensional T1-weighted MRI sequences were successfully performed on all subjects, and cerebrospinal fluid samples were obtained from 77%, 68%, and 83% of AD patients, MCI patients, and controls, respectively. Mean MTA score showed a significant increase from controls (left, right: 0.4, 0.3) to MCI patients (0.9, 0.8) to AD patients (2.3, 2.0), whereas mean WMH score did not differ among the three diagnostic groups (between 0.7 and 0.9). The distribution of both MRI markers was comparable to matched US-ADNI subjects. Conclusions: Academic EADC centers can adopt the ADNI platform to enroll MCI and AD patients and older controls with global cognitive and structural imaging features remarkably similar to those of the US-ADNI. © 2008 The Alzheimer's Association.
机译：背景：在北美，阿尔茨海默氏病神经成像计划（ADNI）建立了一个平台来跟踪阿尔茨海默氏病的大脑变化。欧洲已经进行了一项试点研究，以测试采用ADNI平台（试点E-ADNI）的可行性。方法：使用ADNI临床和神经心理学方法，欧洲阿尔茨海默氏病协会（EADC）的七个学术机构招募了19名轻度认知障碍（MCI）患者，22名AD患者和18名老年人。符合ADNI的磁共振成像（MRI）扫描，脑脊液和血液样本被运送到中央存储库。内侧颞萎缩（MTA）和白质高强度（WMH）由单个评定者使用视觉评定量表进行评估。结果：招聘率为每个站点每月3.5个主题。欧洲受试者的认知，行为和神经心理学特征与美国受试者非常相似。在所有受试者上成功执行了三维T1加权MRI序列，分别从77％，68％和83％的AD患者，MCI患者和对照中获得了脑脊液样本。平均MTA评分显示从对照组（左，右：0.4、0.3）到MCI患者（0.9、0.8）到AD患者（2.3、2.0）有显着提高，而三个诊断组之间的WMH评分无差异（0.7之间）和0.9）。两种MRI标记的分布与匹配的US-ADNI受试者相当。结论：EADC学术中心可以采用ADNI平台招募MCI和AD患者以及具有全球认知和结构成像特征的老年对照，这些特征与US-ADNI极为相似。 ©2008年阿尔茨海默氏症协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号